Sermorelin
Sermorelin is a synthetic peptide. It is a 29-amino acid polypeptide analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to increase the body’s natural production of human growth hormone (hGH).
Key Benefits of Using
- May help support natural growth hormone production
- Commonly researched for improving recovery, lean muscle support, and exercise performance
- May promote better sleep quality and overnight recovery
- Research suggests potential benefits for healthy aging, energy levels, and body composition
FDA-Approved Uses
⚠️ IMPORTANT REGULATORY STATUS ⚠️
Sermorelin was originally FDA-approved in 1997 for pediatric GHD. The commercial manufacturer (Serono) discontinued production in 2008 for commercial/economic reasons — NOT due to safety concerns. As of 2026, NO commercially manufactured FDA-approved sermorelin product exists in the US. It is legally available only through licensed 503A compounding pharmacies with a valid prescription. It is NOT a controlled substance.
Original FDA-approved indication (Geref — discontinued):
1. Long-term treatment of idiopathic growth hormone deficiency (GHD) in children with growth failure — to stimulate and sustain increased plasma GH levels and increase growth rate.
Common off-label uses (not FDA-approved):
– Growth hormone deficiency in adults (via compounding)
– Anti-aging / body composition therapy in adults
[⚠️ Adult off-label use is not validated by FDA review; clinical evidence is more limited]
Trade Names in USA and Manufacturers
– Geref (sermorelin acetate for injection) — formerly Serono Laboratories; DISCONTINUED in US market (~2008).
– Gerel — alternative brand name; also discontinued.
– No FDA-approved commercially manufactured brand currently available in the US.
– Currently available ONLY through licensed 503A compounding pharmacies as a compounded product prepared per individual prescription.
– Multiple compounding pharmacies supply sermorelin as a lyophilized powder requiring reconstitution prior to subcutaneous injection.
Dosage
Pediatric — original FDA-approved dosing (historical prescribing information):
Children with GHD:
0.03 mg/kg body weight subcutaneously once daily at bedtime
[Adjusted based on growth response and IGF-1 levels; continued until near-adult height]
Adults — Compounded / Off-label (not FDA-approved; varies by prescriber):
Typical range: 200–300 mcg subcutaneously once daily at bedtime
[Some protocols use twice-daily; duration individualized by prescriber based on IGF-1, GH stimulation tests, and clinical response]
Reconstitution:
Lyophilized powder; reconstitute with Bacteriostatic Water or Sodium Chloride Injection.
Store reconstituted solution refrigerated (2–8°C). Do not freeze.
Pricing
No commercial (FDA-approved) pricing exists.
Pricing is from compounding pharmacies only.
Approximate monthly costs (compounded sermorelin with prescription):
Typical adult dose (30-day supply): ~$100–$250/month
[Varies significantly by compounding pharmacy, dose, and location]
Additional costs:
Physician consultation fees
Required lab tests (IGF-1, GH stimulation, thyroid panel)
Supplies (syringes, alcohol swabs, sharps container)
Coverage by Insurance Type
⚠️ Coverage is very limited due to discontinued FDA-approved status.
1. ACA Marketplace: Not typically covered; compounded drugs rarely reimbursed ❌
2. Employer Insurance: Some plans may cover documented pediatric GHD with prior auth; adult off-label use typically not covered ⚠️
3. Medicare Part D: Generally not covered for compounded/off-label use ❌
4. Medicaid: Generally not covered for compounded/off-label use ❌
5. TRICARE (Military): Limited; verify with plan ⚠️
Note: When covering GH-related therapy, insurers typically prefer FDA-approved recombinant human growth hormone (rhGH) products over compounded sermorelin.
Tips
– A valid prescription from a licensed physician is required for compounded sermorelin. Do not obtain from unregulated online sources.
– Baseline lab work before and during treatment: IGF-1, fasting insulin, thyroid function, comprehensive metabolic panel.
– Sermorelin stimulates the body’s own GH release (via pituitary) — key difference from direct rhGH. The pituitary’s natural negative feedback (via somatostatin) limits risk of excessive GH levels, unlike exogenous rhGH.
– Use only accredited, reputable 503A pharmacies following USP <797> sterile compounding standards.
– Sermorelin is not subject to the same federal restrictions as synthetic rhGH (which has restricted off-label use under the Anabolic Steroid Control Act framework).
– Inject at bedtime to align with the body’s natural circadian GH release pattern (GH secreted predominantly during deep sleep).
Side Effects
Common:
– Pain, redness, swelling, or itching at injection site (most commonly reported).
– Facial flushing.
– Headache.
– Nausea and vomiting.
– Pallor (paleness).
– Unusual or strange taste in the mouth.
Less common:
– Dizziness.
– Hyperactivity or restlessness (reported in some pediatric patients).
– Somnolence (drowsiness).
– Transient elevated blood glucose (GH can promote insulin resistance).
– Antibody formation: May reduce efficacy over time; observed in some trial participants.
– Hypothyroidism: GH therapy can unmask or worsen subclinical hypothyroidism; thyroid monitoring recommended.
Rare/Serious:
– Changes in heart rate and blood pressure (overdose context).
– Hypersensitivity reactions.
Contraindications
– Known hypersensitivity to sermorelin acetate or any component of the formulation.
– Active intracranial lesion or evidence of tumor growth: Do not use until treatment complete and tumor inactive (risk of stimulating GH-sensitive tissue).
– Untreated hypothyroidism: Reduces GH response; correct thyroid deficiency before initiating.
– Pregnancy: No adequate studies; use not recommended.
– Breastfeeding: Exercise caution; unknown if excreted in human milk.
– Obesity/high body fat: Shown to reduce GH response to GHRH stimulation; may be less effective in significantly obese individuals.
Drug interactions:
– Glucocorticoids (e.g., prednisone) and COX inhibitors (e.g., aspirin, indomethacin) can blunt GH response.
– Insulin, propylthiouracil, and muscarinic antagonists (e.g., atropine) may interact.
Pharmacology
Sermorelin acetate is a synthetic peptide comprising the first 29 amino acids of endogenous human GHRH (positions 1–29), the shortest known fragment of GHRH retaining full biological activity. Designated GHRH(1–29)-NH₂ (C-terminal amide). Contains 29 amino acids; MW ~3,358 daltons. Provided as sterile lyophilized powder for reconstitution. Administered subcutaneously. Plasma half-life ~10–20 minutes (very short) — once-daily bedtime dosing exploits the pituitary’s increased responsiveness during early sleep. Unlike rhGH, sermorelin does not directly introduce exogenous GH — it stimulates the patient’s own pituitary to produce and release GH endogenously.
Mechanism of action
Sermorelin binds to G-protein coupled GHRH receptors (GHRHR) on somatotroph cells of the anterior pituitary gland.
Binding activates adenylyl cyclase → increases intracellular cAMP → stimulates synthesis and secretion of GH from pituitary into bloodstream.
Key regulatory features:
– Natural negative feedback: Somatostatin (hypothalamic) can suppress GH release even in the presence of sermorelin — makes it difficult to cause GH excess (unlike direct rhGH injections).
– Increased GH → liver and other tissues produce IGF-1 → mediates growth-promoting and metabolic effects (protein synthesis, bone growth, lipolysis).
– In children with GHD: stimulation of GH promotes linear bone growth and development.
– In adults (off-label): intent is to restore IGF-1 to normal range — proponents claim improved body composition, bone density, and energy.
Result Claims By Different Companies
Serono Laboratories (original manufacturer of Geref — historical FDA approval data, 1997):
– Demonstrated statistically significant increases in growth rate (height velocity) in children with idiopathic GHD vs. placebo in pivotal clinical trials supporting FDA approval.
– Demonstrated increases in mean plasma GH levels following administration.
– Growth rate increases sustained over 12–24 months of treatment in pediatric GHD subjects.
Off-label adult use claims (from compounding clinics/prescribers — NOT FDA-verified):
– Some clinicians claim sermorelin may improve body composition (reduce fat, increase lean mass), energy, sleep quality, and bone density in adults with GHD.
– These claims are based on smaller clinical studies and clinical experience — not large Phase 3 trials — and have NOT been reviewed or verified by the FDA for adult indications.
– Patients should approach adult off-label claims with appropriate caution and consult a qualified physician.
Disclaimer
This content about “Sermorelin” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.